Thursday, December 31, 2009
"Ovarian disease (cancer) was diagnosed at a median of 5 years after breast cancer. Seventy-five percent of patients were asymptomatic, and advanced-stage pelvic extent or extra-abdominal metastases were observed in 41.5% of patients. The median survival was 3 years..."
"...A, E, D can cause serious adverse events."
CONCLUSIONS: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.
we do not have a proven biomarker, panel of biomarkers, or overall screening program that works well. The current report, with its sobering implications, brings us closer to understanding the crucial elements in designing any effective early detection program for ovarian cancer...."
free full access: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- JNCI
Note: small study, did not include family history of colorectal cancer (Lynch Syndrome); clear cell ovarian subtype
THE RESEARCH ARTICLE:
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al., 10.1093/jnci/djp438 -- JNCI Journal of the National Cancer Institute